- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Indacaterol 150 µg, Salmeterol 50 µg, Placebo to indacaterol, Placebo to salmeterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 74
- States / cities
- Anniston, Alabama • Fairhope, Alabama • Jasper, Alabama + 69 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Asthma
- Interventions
- Indacaterol, Salmeterol, Placebo to Indacaterol, Placebo to Salmeterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 71
- States / cities
- Glendale, Arizona • Scottsdale, Arizona • Encinitas, California + 64 more
- Conditions
- COPD
- Interventions
- Indacaterol, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 93
- States / cities
- Homewood, Alabama • Jasper, Alabama • Phoenix, Arizona + 83 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg), Placebo to Indacaterol, Placebo to Salmeterol/fluticasone, Placebo to salbutamol
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 5
- States / cities
- Tamarac, Florida • Lafayette, Louisiana • Saint Charles, Missouri + 2 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol, Placebo to tiotropium
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,598 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 22 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
- Interventions
- Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,059 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 221
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Homewood, Alabama + 163 more
- Conditions
- Healthy Volunteers, Chronic Obstructive Pulmonary Disease
- Interventions
- Indacaterol 150 µg, Indacaterol 300 µg, Indacaterol 600 µg, Placebo, Placebo/moxifloxacin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 404 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Asthma
- Interventions
- Indacaterol acetate/Mometasone furoate, Mometasone furoate, Salmeterol xinafoate/fluticasone propionate
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 2,216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 26 more
- Conditions
- Persistent Asthma
- Interventions
- Indacaterol, Placebo to Indacaterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 21
- States / cities
- Anniston, Alabama • Cypress, California • Fresno, California + 16 more
- Conditions
- Asthma
- Interventions
- indacaterol maleate
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 5
- States / cities
- Denver, Colorado • North Dartmouth, Massachusetts • Minneapolis, Minnesota + 2 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 116
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more